A Biohub study published in Science Translational Medicine reports that co‑administering a three‑amino‑acid cocktail dramatically enhances lipid nanoparticle (LNP) uptake in vivo, improving mRNA delivery and CRISPR editing efficiency in preclinical models. Investigators found that physiological metabolic contexts suppress amino‑acid metabolic programs that limit LNP fusion; supplementing selected amino acids restored cellular receptivity. Authors from Biohub and collaborators showed the approach increased editing and expression without altering nanoparticle chemistry, suggesting an immediately translatable co‑administration strategy for existing LNP formulations. The team highlighted potential for broad applicability across mRNA vaccines, gene editing and therapeutic RNA programs. If replicated in larger animal and human studies, the discovery could lift a major translational barrier for nucleic‑acid medicines by improving in‑body delivery without needing complex reformulation—shortening development timelines and reducing reformulation costs for programs stalled by delivery inefficiency.